Cargando…

Potential added value of combined DPYD/DPD genotyping and phenotyping to prevent severe toxicity in patients with a DPYD variant and decreased dihydropyrimidine dehydrogenase enzyme activity

Decreased dihydropyrimidine dehydrogenase enzyme activity is associated with severe fluoropyrimidine-associated toxicity. Four clinically relevant variants in the DPYD gene are associated with decreased dihydropyrimidine dehydrogenase activity. However, only ∼25% of DPYD variant carriers show a decr...

Descripción completa

Detalles Bibliográficos
Autores principales: Ockeloen, Charlotte W, Raaijmakers, Aron, Hijmans-van der Vegt, Manon, Bierau, Jörgen, de Vos-Geelen, Judith, Willemsen, Annelieke ECAB, van den Bosch, Bianca JC, Coenen, Marieke JH
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9749565/
https://www.ncbi.nlm.nih.gov/pubmed/34797200
http://dx.doi.org/10.1177/10781552211049144
_version_ 1784850061376618496
author Ockeloen, Charlotte W
Raaijmakers, Aron
Hijmans-van der Vegt, Manon
Bierau, Jörgen
de Vos-Geelen, Judith
Willemsen, Annelieke ECAB
van den Bosch, Bianca JC
Coenen, Marieke JH
author_facet Ockeloen, Charlotte W
Raaijmakers, Aron
Hijmans-van der Vegt, Manon
Bierau, Jörgen
de Vos-Geelen, Judith
Willemsen, Annelieke ECAB
van den Bosch, Bianca JC
Coenen, Marieke JH
author_sort Ockeloen, Charlotte W
collection PubMed
description Decreased dihydropyrimidine dehydrogenase enzyme activity is associated with severe fluoropyrimidine-associated toxicity. Four clinically relevant variants in the DPYD gene are associated with decreased dihydropyrimidine dehydrogenase activity. However, only ∼25% of DPYD variant carriers show a decreased dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells. OBJECTIVE: To investigate if dihydropyrimidine dehydrogenase phenotyping has added value when combined with DPYD genotyping in predicting fluoropyrimidine-related toxicity. METHODS: Retrospective cohort study in which treatment and toxicity data were collected of 228 patients genotyped for four DPYD variants and phenotyped using an ex vivo peripheral blood mononuclear cell assay. RESULTS: Severe toxicity occurred in 25% of patients with a variant and normal dihydropyrimidine dehydrogenase activity, in 21% of patients without a variant and with decreased dihydropyrimidine dehydrogenase activity, and in 29% of patients without a variant and with normal dihydropyrimidine dehydrogenase activity (controls). The majority of patients with a variant or a decreased dihydropyrimidine dehydrogenase activity received an initial dose reduction (68% and 53% vs 19% in controls) and had a lower mean dose intensity (75% and 81% vs 91% in controls). Fifty percent of patients with a variant and decreased enzyme activity experienced severe toxicity, despite the lowest initial dose and whole treatment dose intensity. They also experienced more grade 4/5 toxicities. CONCLUSIONS: Our results indicate that a combined genotype–phenotype approach could be useful to identify patients at increased risk for fluoropyrimidine-associated toxicity (e.g. patients with a variant and decreased dihydropyrimidine dehydrogenase activity). Because the group sizes are too small to demonstrate statistically significant differences, this warrants further research in a prospective study in a larger cohort.
format Online
Article
Text
id pubmed-9749565
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-97495652022-12-15 Potential added value of combined DPYD/DPD genotyping and phenotyping to prevent severe toxicity in patients with a DPYD variant and decreased dihydropyrimidine dehydrogenase enzyme activity Ockeloen, Charlotte W Raaijmakers, Aron Hijmans-van der Vegt, Manon Bierau, Jörgen de Vos-Geelen, Judith Willemsen, Annelieke ECAB van den Bosch, Bianca JC Coenen, Marieke JH J Oncol Pharm Pract Original Articles Decreased dihydropyrimidine dehydrogenase enzyme activity is associated with severe fluoropyrimidine-associated toxicity. Four clinically relevant variants in the DPYD gene are associated with decreased dihydropyrimidine dehydrogenase activity. However, only ∼25% of DPYD variant carriers show a decreased dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells. OBJECTIVE: To investigate if dihydropyrimidine dehydrogenase phenotyping has added value when combined with DPYD genotyping in predicting fluoropyrimidine-related toxicity. METHODS: Retrospective cohort study in which treatment and toxicity data were collected of 228 patients genotyped for four DPYD variants and phenotyped using an ex vivo peripheral blood mononuclear cell assay. RESULTS: Severe toxicity occurred in 25% of patients with a variant and normal dihydropyrimidine dehydrogenase activity, in 21% of patients without a variant and with decreased dihydropyrimidine dehydrogenase activity, and in 29% of patients without a variant and with normal dihydropyrimidine dehydrogenase activity (controls). The majority of patients with a variant or a decreased dihydropyrimidine dehydrogenase activity received an initial dose reduction (68% and 53% vs 19% in controls) and had a lower mean dose intensity (75% and 81% vs 91% in controls). Fifty percent of patients with a variant and decreased enzyme activity experienced severe toxicity, despite the lowest initial dose and whole treatment dose intensity. They also experienced more grade 4/5 toxicities. CONCLUSIONS: Our results indicate that a combined genotype–phenotype approach could be useful to identify patients at increased risk for fluoropyrimidine-associated toxicity (e.g. patients with a variant and decreased dihydropyrimidine dehydrogenase activity). Because the group sizes are too small to demonstrate statistically significant differences, this warrants further research in a prospective study in a larger cohort. SAGE Publications 2021-11-19 2023-01 /pmc/articles/PMC9749565/ /pubmed/34797200 http://dx.doi.org/10.1177/10781552211049144 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Articles
Ockeloen, Charlotte W
Raaijmakers, Aron
Hijmans-van der Vegt, Manon
Bierau, Jörgen
de Vos-Geelen, Judith
Willemsen, Annelieke ECAB
van den Bosch, Bianca JC
Coenen, Marieke JH
Potential added value of combined DPYD/DPD genotyping and phenotyping to prevent severe toxicity in patients with a DPYD variant and decreased dihydropyrimidine dehydrogenase enzyme activity
title Potential added value of combined DPYD/DPD genotyping and phenotyping to prevent severe toxicity in patients with a DPYD variant and decreased dihydropyrimidine dehydrogenase enzyme activity
title_full Potential added value of combined DPYD/DPD genotyping and phenotyping to prevent severe toxicity in patients with a DPYD variant and decreased dihydropyrimidine dehydrogenase enzyme activity
title_fullStr Potential added value of combined DPYD/DPD genotyping and phenotyping to prevent severe toxicity in patients with a DPYD variant and decreased dihydropyrimidine dehydrogenase enzyme activity
title_full_unstemmed Potential added value of combined DPYD/DPD genotyping and phenotyping to prevent severe toxicity in patients with a DPYD variant and decreased dihydropyrimidine dehydrogenase enzyme activity
title_short Potential added value of combined DPYD/DPD genotyping and phenotyping to prevent severe toxicity in patients with a DPYD variant and decreased dihydropyrimidine dehydrogenase enzyme activity
title_sort potential added value of combined dpyd/dpd genotyping and phenotyping to prevent severe toxicity in patients with a dpyd variant and decreased dihydropyrimidine dehydrogenase enzyme activity
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9749565/
https://www.ncbi.nlm.nih.gov/pubmed/34797200
http://dx.doi.org/10.1177/10781552211049144
work_keys_str_mv AT ockeloencharlottew potentialaddedvalueofcombineddpyddpdgenotypingandphenotypingtopreventseveretoxicityinpatientswithadpydvariantanddecreaseddihydropyrimidinedehydrogenaseenzymeactivity
AT raaijmakersaron potentialaddedvalueofcombineddpyddpdgenotypingandphenotypingtopreventseveretoxicityinpatientswithadpydvariantanddecreaseddihydropyrimidinedehydrogenaseenzymeactivity
AT hijmansvandervegtmanon potentialaddedvalueofcombineddpyddpdgenotypingandphenotypingtopreventseveretoxicityinpatientswithadpydvariantanddecreaseddihydropyrimidinedehydrogenaseenzymeactivity
AT bieraujorgen potentialaddedvalueofcombineddpyddpdgenotypingandphenotypingtopreventseveretoxicityinpatientswithadpydvariantanddecreaseddihydropyrimidinedehydrogenaseenzymeactivity
AT devosgeelenjudith potentialaddedvalueofcombineddpyddpdgenotypingandphenotypingtopreventseveretoxicityinpatientswithadpydvariantanddecreaseddihydropyrimidinedehydrogenaseenzymeactivity
AT willemsenanneliekeecab potentialaddedvalueofcombineddpyddpdgenotypingandphenotypingtopreventseveretoxicityinpatientswithadpydvariantanddecreaseddihydropyrimidinedehydrogenaseenzymeactivity
AT vandenboschbiancajc potentialaddedvalueofcombineddpyddpdgenotypingandphenotypingtopreventseveretoxicityinpatientswithadpydvariantanddecreaseddihydropyrimidinedehydrogenaseenzymeactivity
AT coenenmariekejh potentialaddedvalueofcombineddpyddpdgenotypingandphenotypingtopreventseveretoxicityinpatientswithadpydvariantanddecreaseddihydropyrimidinedehydrogenaseenzymeactivity